ArticleBlood advances2023

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.

Kunal C Potnis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.